###### Strengths and limitations of this study

-   This study evaluated the cost-effectiveness of rivaroxaban for acute deep vein thrombosis treatment in China with a well-acknowledged and transparent method.

-   This study could support the decision-making of stakeholders in China, including hospitals, payers and physicians.

-   In this analysis, we set a lot of assumptions, in terms of patients' characteristics, inpatient setting and the treatment duration, which may limit the results being extrapolated to whole population.

-   The utility data in the model were derived from literature and not specific to the Chinese population, which may impact the estimation of quality-adjusted life year.

Introduction {#s1}
============

Deep vein thrombosis (DVT) and pulmonary embolism (PE) together constitute venous thromboembolism (VTE)---a common disorder causing substantial disease burden and mortality globally.[@R1] In China, the incidence of VTE (DVT and PE) is high among hospitalised patients,[@R2] with incidence rate of 30.0, 8.7 and 3.0 per 100 000 reported for DVT, PE and PE with DVT in a large epidemiological study in Chinese population. In addition, mortality rates of DVT, PE and PE with DVT were 9.0%, 17.4% and 13.3%, respectively.[@R4] Consistent with this, VTE is among the major causes of death in hospitals.[@R5] Clinical guidelines recommend the use of anticoagulant therapy to minimise the risk of mortality and VTE recurrence, with low-molecular weight heparin (LMWH) overlapped with vitamin-K-antagonists (VKAs; mostly warfarin) being one of the current standard of care (SoC).[@R6] However, there are several limitations to the SoC, for example, patients requiring injection, frequent international normalisation ratio (INR) monitoring and dose titrations,[@R7] which result in unsatisfactory compliance and therapeutic outcomes in clinical practice.[@R7]

Rivaroxaban, an orally administered anticoagulant which does not require frequent monitoring or dose adjustments,[@R8] when compared with enoxaparin plus warfarin (enoxaparin/warfarin), displayed similar efficacy and safety in preventing recurrent DVT and reducing the risk of bleeding events, as reported in the EINSTEIN-DVT trial.[@R11] Evidence from several studies also suggests that rivaroxaban treatment results in a significant decrease in the number of hospitalisations and outpatient visits as well as a reduction in total hospitalisation costs.[@R12]

Although rivaroxaban has been approved for DVT treatment in China, its higher price[@R14] compared with warfarin might be a barrier for some patients and payers. To address the concern of limited cost-effectiveness evidence for rivaroxaban and enoxaparin/warfarin in DVT, this study aimed to evaluate the cost-effectiveness of rivaroxaban versus enoxaparin/warfarin from a Chinese healthcare perspective based on findings of the EINSTEIN-DVT trial.[@R15]

Methods {#s2}
=======

A Markov model was developed to estimate the cost-effectiveness of rivaroxaban compared with enoxaparin/warfarin in the treatment of patients with acute DVT in hospitals, from the Chinese healthcare payer perspective, for a duration of 5 years. The duration was set based on the previous publication[@R16] and clinical practice in China. The results of our study were reported using the Consolidated Health Economic Evaluation Reporting Standards.[@R17]

The patients evaluated in our model met the description of participants from the acute DVT arm of the EINSTEIN-DVT trial.[@R15] All patients' age was set to 56 years at baseline as per the EINSTEIN study. The patients entered the model in the 'on-treatment' state and received oral rivaroxaban (15 mg two times per day for 21 days followed by 20 mg per day) or enoxaparin (1.0 mg/kg subcutaneously for 8 days) plus warfarin (target INR of 2.0--3.0). Based on the perception that, in Chinese clinical practice, the actual anticoagulant treatment duration for patients with DVT is \<3 months, the model assumed that all patients had received 3 months of anticoagulation treatment. The model also assumed that all patients received inpatient treatment in the acute phase, because the main risk factors of acute DVT events in China were prolonged immobilisation and malignant tumours[@R18] and those patients were most likely to get treatment in inpatient setting when DVT was provoked.

The outcomes of the model included assessment of quality-adjusted life years (QALYs) and cost of treatment with rivaroxaban or enoxaparin/warfarin. Factors affecting the cost-effectiveness model were also determined. The model allowed tracking of patients with DVT through a standard treatment pathway and captured the common complications associated with DVT and its anticoagulant treatment. Probabilities of treatment discontinuation due to bleeding or non-compliance were also considered in the model. A 3-month cycle length with a 5-year time horizon was used. Total medical costs were considered from a Chinese healthcare perspective and expressed as the 2017 USD exchange rate (US\$1=¥6.67), with future costs discounted at 5% per year.

Model framework {#s2-1}
---------------

The Markov model was developed with 12 health states ([figure 1](#F1){ref-type="fig"}) and presents progression between health states according to transition probabilities. The model also shows the estimates of life expectancy, health outcomes, resource use and cost of treatment. As per the model, patients were assumed to be on-treatment on initiation of either rivaroxaban or enoxaparin treatment after an index DVT event. Post-therapy, the patients may undergo several transition states, including acute bleeding events such as major intracranial (IC) bleeding, extracranial (EC) or clinically relevant non-major (CRNM) bleeding as well as recurrent VTE events (DVT or PE). The common long-term complications were considered in the model, including post-IC bleed state following IC bleed events, chronic thromboembolic pulmonary hypertension (CTEPH) after PE events and post-thrombotic syndrome (PTS) after DVT events. Recurrent DVT, risk of CTEPH and death were also considered in patients not receiving therapy. Each state was assigned a cost and utility weighting to calculate the total costs and QALYs of patients simulated in the model.[@R19]

![Model schematic.[@R21] \*DVT split into contralateral and ipsilateral. \*\*Additional mortality. CRNM, clinically relevant non-major; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.](bmjopen-2020-038433f01){#F1}

Model inputs {#s2-2}
------------

### Core clinical data {#s2-2-1}

The clinical inputs used in the model, regarding the cost, safety and probability of events for both rivaroxaban and SoC, were obtained from the EINSTEIN-DVT study.[@R15] The trial is a multicentre, randomised, open-label, event-driven powered to show non-inferiority against warfarin. Total 3449 patients were included in the study: 1731 given rivaroxaban and 1718 given enoxaparin plus a VKA. The primary efficacy outcome was recurrent VTE and the principal safety outcome was major bleeding or CRNM.

For the time period of 0--3 months (cycle 1), event data for recurrent VTE, major bleeding (both IC and EC bleedings) and CRNM bleeding were considered as the baseline ([table 1](#T1){ref-type="table"}).[@R15] The probability of events with rivaroxaban in cycle 1 was inputted from the HR of rivaroxaban compared with enoxaparin/warfarin. Transition probabilities per cycle were calculated based on event risk. This was mainly derived from the EINSTEIN-DVT trial and other published literature.[@R20]

###### 

Model inputs

                                                                                       Base case (lower--upper)   Distribution   Source
  ------------------------------------------------------------------------------------ -------------------------- -------------- ----------------------------------------------------------------------------
  Baseline events risk (0--3 months)---enoxaparin/warfarin                                                                       
   rVTE                                                                                2.6% (1.8%--3.3%)          Beta           EINSTEIN-DVT[@R15]
   Probability that rVTE is DVT                                                        48.3% (37.8%--58.8%)       Beta           EINSTEIN-DVT[@R15]
   Major bleeding                                                                      0.9% (0.4%--1.3%)          Beta           EINSTEIN-DVT[@R15]
   Probability major bleeding is intracranial bleeding                                 12.5% (1%--24%)            Beta           EINSTEIN-DVT[@R15]
   CRNM bleeding                                                                       4.9% (3.9%--5.9%)          Beta           EINSTEIN-DVT[@R15]
  HR---rivaroxaban versus enoxaparin/warfarin                                                                                    
   rVTE                                                                                0.68 (0.44--1.04)          Log-normal     EINSTEIN-DVT[@R15]
   Major bleeding                                                                      0.65 (0.33--1.30)          Log-normal     EINSTEIN-DVT[@R15]
   CRNM bleeding                                                                       1.055 (0.828--1.342)       Log-normal     EINSTEIN-DVT[@R15]
  Events risk---long-term complications                                                                                          
   rVTE (10 year risk)                                                                 39.9% (35.4%--44.4%)       Beta           Prandoni *et al*[@R20]
   Bleeding (subsequent cycles)                                                        0                          --             Assumption
   Postintracranial bleeding                                                           56.4%                      --             Linkins *et al*[@R21]
   CTEPH (2-year risk)                                                                 1.25% (1.14%--1.63%)       Beta           Miniati *et al*[@R22]
   PTS (1-year risk)                                                                   18% (14.7%--21.3%)         Beta           Prandoni *et al*[@R23]
  Mortality                                                                                                                      
   PE                                                                                  25.0% (17%--33%)           Beta           EINSTEIN-DVT[@R15]
   DVT                                                                                 0.0%                       --             Assumption
   Intracranial bleeding                                                               43.6% (36.5%--50.7%)       Beta           Linkins *et al*[@R21]
   Major extracranial bleeding                                                         3.9% (2.7%--5.4%)          Beta           Linkins *et al*[@R21]
   CTEPH (3-year mortality)                                                            26.0% (22%--30%)           Beta           Condliffe *et al*[@R24]
  Utility scores                                                                                                                 
   Population norm                                                                     0.929 (0.917--0.941)       Beta           Guan and Liu[@R25]
   DVT                                                                                 0.884 (0.674--1.000)       Beta           Locadia *et al*[@R26]
   PE                                                                                  0.663 (0.379--0.905)       Beta           Locadia *et al*[@R26]
   Intracranial bleeding                                                               0.347 (0.147--0.558)       Beta           Locadia *et al*[@R26]
   Major extracranial bleeding                                                         0.684 (0.516--0.905)       Beta           Locadia *et al*[@R26]
   CRNM bleeding                                                                       1.000                      Beta           Assumption
   Postintracranial bleeding                                                           0.713 (0.702--0.724)       Beta           Rivero-Aries *et al*[@R28]
   CTEPH                                                                               0.560 (0.528--0.592)       Beta           Meads *et al*[@R29]
   Mild PTS                                                                            1.000 (0.91--1.00)         Beta           Lenert and Soetikno[@R30]
   Severe PTS                                                                          0.93 (0.76--1.00)          Beta           Lenert and Soetikno[@R30]
   Warfarin (disutility)                                                               0.988 (0.95--1.00)         Beta           Marchetti *et al*[@R31]
   Enoxaparin (disutility)                                                             0.988 (0.95--1.00)         --             Assumption
   Rivaroxaban (disutility)                                                            1.000                      --             Assumption
   Drug costs (US\$)                                                                                                             Integrated Management Platform of Beijing Medicine Sunshine Purchase[@R14]
   Rivaroxaban (price/15 mg tablet)                                                    4.17 (2.92--5.42)          --             
   Rivaroxaban (price/20 mg tablet)                                                    5.19 (3.63--6.75)          --             
   Warfarin (price/3 mg tablet/day)                                                    0.08 (0.06--0.10)          --             
   Enoxaparin (6000 units: 0.6 mL)                                                     8.71 (6.10--11.32)         --             
  Monitoring cost (US\$)                                                                                                         
   Warfarin monitoring (per time)                                                      10.98 (7.69--14.27)        Gamma          Local charge
   Rivaroxaban monitoring (per time)                                                   10.98 (7.69--14.27)        Gamma          Assumption
  Costs of events (US\$)                                                                                                          
   rVTE--DVT                                                                           3853 (2697--5009)          Gamma          Li *et al*[@R33]
   rVTE--PE                                                                            4083(2858--5308)           Gamma          Li *et al*[@R33]
   CRNM bleeding                                                                       8.25 (5.77--10.72)         Gamma          Wu *et al*[@R34]
   Major bleeding (extracranial)                                                       2999 (2099--3898)          Gamma          Wu *et al*[@R34]
   Major bleeding (intracranial)                                                       3834 (2684--4984)          Gamma          Wu *et al*[@R34]
   Postintracranial bleeding                                                           339.6 (237.7--441.5)       Gamma          Wu *et al*[@R34]
   Mild/moderate PTS                                                                   59.97 (41.98--77.96)       Gamma          Chen *et al*[@R35]
   Severe PTS                                                                          487.3 (341.1--633.4)       Gamma          Chen *et al*[@R35]
   CTEPH                                                                               4873 (3411--6334)          Gamma          Chen *et al*[@R35]
  Resource utilisation for acute DVT treatment                                                                                   
   Days of enoxaparin injection                                                        8 (6--11)                  Normal         EINSTEIN-DVT[@R15]
   Frequency of monitoring---enoxaparin/warfarin                                       8 (5.6--10.4)              Gamma          Assumption
   Frequency of monitoring---rivaroxaban                                               3 (2.1--3.9)               Gamma          Assumption
   Length of stay of patients---enoxaparin/warfarin                                    14.6 (10.22--18.98)        Gamma          Wu *et al*[@R7]
   Difference in length of stay of patients---rivaroxaban versus enoxaparin/warfarin   3 (2.1--3.9)               Gamma          van Bellen *et al*[@R32]

CRNM, clinically relevant non-major; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; PE, pulmonary embolism; PTS, post-thrombotic syndrome; rVTE, recurrent venous thromboembolism.

Risk of post-treatment events including recurrent VTE, bleeding, PTS, CTEPH and event-specific mortality rates in subsequent cycles were obtained from the published literature ([table 1](#T1){ref-type="table"}).

### Discontinuation rates {#s2-2-2}

Based on findings from the EINSTEIN-DVT study, the model assumed that all patients with IC bleeding, 40% of patients with major EC bleeding and 11.3% of those with CRNM bleeding would discontinue the treatment. Complete discontinuation was assumed for patients with major bleeding events. However, for CRNM bleeding events, it was assumed that patients would discontinue therapy for 1 month only and treatment costs would be incurred for the remainder of the cycle.

### Utility inputs {#s2-2-3}

Utility values define health state associated quality of life with a range of 0--1 (0=death and 1=best estimated health state). Evidence from published literature was used to determine the various utility values. The Chinese population norm value was taken as 0.929 (95% CI 0.917 to 0.941), which was established in the landmark national EuroQol five dimensions questionnaire (EQ-5D) survey.[@R25] This value was used as the basis for calculating the utilities of every health state. The utility value used for DVT was 0.884 (95% CI 0.674 to 1.000), as demonstrated in the report by Locadia *et al*.[@R26] Previous studies[@R27] have reported increased treatment satisfaction with rivaroxaban compared with enoxaparin/warfarin; therefore, a disutility weight of 1.00 was assumed for rivaroxaban and a disutility value of 0.988 was assumed for enoxaparin/warfarin. Utilities for other states were based on values in the previously published literature[@R26] ([table 1](#T1){ref-type="table"}).

### Resource utilisation and cost inputs {#s2-2-4}

On entry into the model, resource utilisation related to the index event (DVT) was used to analyse the difference between rivaroxaban and enoxaparin/warfarin, especially in terms of drug utilisation, monitoring frequency and hospitalisation. We assumed that patients received standard dosage and 3 months treatment in the absence of contraindications. It was also conservatively assumed that, in the first 3 months, patients receiving rivaroxaban would require three drug-monitoring visits and patients receiving enoxaparin/warfarin therapy would require eight visits. The length of stay (LoS) for hospitalised patients with DVT was set as 14.6 days (range 10.22--18.98 days) with enoxaparin/warfarin treatment[@R7] and was assumed to be 3 days shorter with rivaroxaban therapy.[@R32] Unit costs of rivaroxaban, enoxaparin and warfarin were based on local drug tariffs in China ([table 1](#T1){ref-type="table"}). The daily cost of hospitalisation was based on published literature (US\$363.65, range US\$254.55--472.74),[@R33] with an average LoS of 14.6 days (range 10.22--18.98 days) for patients receiving enoxaparin/warfarin.[@R7] The costs of managing the event were also based on the published literature[@R33] and assumed to be equal across all treatment arms ([table 1](#T1){ref-type="table"}).

Data analysis {#s2-3}
-------------

Data from published studies and assumptions from [table 1](#T1){ref-type="table"} were used to calculate mean estimates of 5-year costs and QALYs for rivaroxaban and enoxaparin/warfarin. Base-case analyses---total costs and QALYs---were calculated for patients receiving rivaroxaban or SoC. Furthermore, the incremental cost-effectiveness ratio (ICER) was also calculated. Besides, we assumed a willingness-to-pay (WTP) threshold of US\$14 992.5 per QALY (ie, ¥100 000 originally in the model), which was less than three times the gross domestic product per capita in China in 2016 (US\$24 351.8[@R36]). An ICER of less than US\$14 992.5 per QALY is then an indication that rivaroxaban is cost-effectiveness.[@R37]

To explore the effect of parameter uncertainty, we conducted one-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA). In OWSA, the minimum and maximum estimates of clinical data, utility and costs were used in the model. For PSA, the variables were specified as distributions: the clinical input followed beta or normal distribution; costs inputs followed gamma distribution and utility data followed beta distribution. Then we run 1000 simulations in PSA to get 1000 estimates of incremental costs and QALYs. All analyses were carried out using Microsoft Excel.

Patient and Public Involvement {#s2-4}
------------------------------

Patients were not involved.

Results {#s3}
=======

Base-case analysis {#s3-1}
------------------

The results of the base-case cost-effectiveness analysis are presented in [table 2](#T2){ref-type="table"}. Treatment with rivaroxaban and enoxaparin/warfarin over a 3-month period, estimated for a time duration of 5 years, showed that rivaroxaban therapy was associated with a gain of 0.008 QALYs, (4.111 QALYs with rivaroxaban compared with 4.103 QALYs with enoxaparin/warfarin). Although the drug acquisition cost of rivaroxaban was higher compared with enoxaparin/warfarin (US\$504.9 vs US\$145.8; difference of US\$359.0), the monitoring cost (US\$24.3 vs US\$64.3; difference of US\$ −40.0) and treatment cost for VTE events (US\$3625.2 vs US\$4770.8; difference of US\$ −1145.5) with rivaroxaban were lower compared with those for enoxaparin/warfarin. This resulted in an overall lower total cost of treatment with rivaroxaban than with enoxaparin/warfarin (US\$4744.4 vs US\$5572.4, respectively; incremental costs US\$ −828.0). The cost of treating bleeding events, PTS and CTEPH were similar with both treatments and did not impact the overall cost of treatment ([table 2](#T2){ref-type="table"}).

###### 

Total costs and QALYs for rivaroxaban and enoxaparin/warfarin

  Outcomes                    Rivaroxaban   Enoxaparin/warfarin   Incremental
  --------------------------- ------------- --------------------- -------------
  Total cost (US\$)           4744.4        5572.4                −828.0
   Drug acquisition cost      504.9         145.8                 359.0
   Monitoring cost            24.3          64.3                  --40.0
   VTE event treatment cost   3625.2        4770.8                --1145.5
   Bleeding treatment cost    33.8          33.7                  0.1
   PTS/CTEPH                  556.1         557.8                 --1.6
  QALY                        4.111         4.103                  0.008
  ICER                        --            --                     Dominant

CTEPH, chronic thromboembolic pulmonary hypertension; ICER, incremental cost-effectiveness ratio; PTS, post-thrombotic syndrome; QALY, quality-adjusted life year; VTE, venous thromboembolism.

One-way sensitivity analysis {#s3-2}
----------------------------

Since rivaroxaban was dominant in the base-case analysis, a net monetary benefit (NMB) OWSA was conducted to examine economic value. The top 10 most sensitive parameters affecting the rivaroxaban and enoxaparin/warfarin cost-effectiveness model are presented in [figure 2](#F2){ref-type="fig"}. According to the OWSA, the cost-effectiveness of rivaroxaban compared with enoxaparin/warfarin was most sensitive to the length of hospital stay of patients on enoxaparin/warfarin, cost per day of hospitalisation and the difference in LoS between patients receiving rivaroxaban and enoxaparin/warfarin; these parameters acted as the main drivers of the cost differences. Overall, rivaroxaban showed a positive NMB irrespective of the parameters or the values used.

![One-way sensitivity analysis tornado diagram for rivaroxaban compared with standard of care (net monetary benefit, quality-adjusted life year based). DVT, deep vein thrombosis; Enox, enoxaparin; LMWH, low-molecular weight heparin; LoS, length of stay; Riva, rivaroxaban; VKA, vitamin-K-antagonists; VTE, venous thromboembolism; WARF, warfarin.](bmjopen-2020-038433f02){#F2}

Probabilistic sensitivity analysis {#s3-3}
----------------------------------

The PSA confirmed the cost-effectiveness of rivaroxaban over enoxaparin/warfarin ([figure 3](#F3){ref-type="fig"}). The majority of simulations showed that 3 months of treatment with rivaroxaban was more cost-effective than the equivalent duration of enoxaparin/warfarin treatment, which resulted in a 99.6% likelihood of rivaroxaban being cost-effective at a WTP threshold of US\$14 992.5 per QALY.

![Cost-effectiveness plane for rivaroxaban versus enoxaparin/warfarin, based on whole study HR (5-year, QALY outcome). QALY, quality-adjusted life year.](bmjopen-2020-038433f03){#F3}

Discussion {#s4}
==========

This study was an economic evaluation of rivaroxaban anticoagulation therapy compared with SoC for DVT treatment from a Chinese healthcare payer perspective. From the base-case analysis, it was observed that, over a 5-year period, rivaroxaban appeared to be more cost-effective than SoC for the treatment of hospitalised acute DVT in China despite having a higher price per unit than warfarin. These results were mainly driven by the lower hospitalisation cost of patients receiving rivaroxaban. The sensitivity analyses also showed the robustness of the model used.

Our findings show that hospitalisation costs for monitoring and VTE-related events were lower with rivaroxaban compared with SoC treatment. Although only 0.008 additional QALYs were achieved with rivaroxaban treatment, the PSA suggested that the probability of rivaroxaban being more cost-effective than SoC treatment would be 99.6% per 1000 iterations, indicating that rivaroxaban has greater cost-saving potential than enoxaparin/warfarin, at a WTP threshold of US\$14 992.5 per QALY.

The results of our study are in line with those presented in the previous studies. Studies in the Western population have demonstrated the cost-effectiveness of rivaroxaban over LMWH/VKA, placebo, LMWH alone and VKA alone for VTE recurrence and other transition events.[@R19] In a cost-effectiveness analysis, rivaroxaban showed per-patient cost savings at 3, 6 and 12 months compared with enoxaparin/warfarin in the EINTEIN DVT trial; the HR of VTE, discount rate and mean age were the driving factors affecting this model.[@R19] Coleman *et al* showed greater QALYs gained with rivaroxaban treatment compared with placebo (16.167 vs 16.134) despite a higher treatment cost (US\$22 645 vs US\$22 083), suggesting the higher cost-effectiveness of rivaroxaban over placebo, assuming a WTP threshold of US\$50 000 per QALYs gained.[@R38] An economic comparison of rivaroxaban and warfarin in the US showed a lower cost of treatment with rivaroxaban (US\$3195 vs US\$6188) as well as more QALYs gained (9.29 QALYs vs 9.14 QALYs). However, rivaroxaban was not more cost-effective than warfarin when major bleeding risk with rivaroxaban exceeded 3.8%.[@R39] Gourzoulidis *et al* reported the cost-effectiveness analysis of rivaroxaban for VTE treatment in Greece from a third-party payer perspective, which also showed that rivaroxaban was cost-effective compared with SoC.[@R40] The findings from all these studies suggest that treatment with rivaroxaban results in greater cost benefits and clinical outcomes from both payer and societal perspectives.

The findings of our study imply that, despite the cost of rivaroxaban being higher than that of warfarin, it has the potential to reduce the overall economic burden of DVT treatment by reducing hospitalisation costs. This is particularly meaningful for the Chinese healthcare system and its hospitals and payers, who are struggling to reduce patient LoS and healthcare expenses.[@R41] With rivaroxaban, patients may have higher utility and satisfaction as well as lower economic burden due to early discharge and convenient disease management methods. However, the duration of anticoagulation and patients' age must be important consideration, as in the previous study, recurrence of VTE was associated with shorter duration of anticoagulation, older age and primary DVT.[@R20]

Although methodological standards were followed for the conduct of this analysis, it has several limitations. First, we set a lot of assumptions in the model which may not reflect real-world clinical practice, for example, all patients were receiving inpatient treatment and the anticoagulant duration was only 3 months with frequent monitoring visits. We then extrapolated the results to wider populations, focusing on the high impact of hospitalisations. Second, clinical and utility data were derived from many sources, some of which were not specific to the Chinese population. For example, the clinical inputs on efficacy and safety were taken from the EINSTEIN-DVT trial, and some of the utilities data came from international literature because of a lack of Chinese-specific sources; therefore, further validation is warranted before applying these findings in real-world treatment settings. However, including the limited economic data available from China were the best possible measure taken to address the concern. Third, our model lacked analyses based on patient/societal perspectives, which may also be beneficial in evaluating the indirect cost of rivaroxaban treatment. Real-world studies would also be useful to evaluate the actual cost-effectiveness of rivaroxaban and further justify its clinical and economic values.

Conclusion {#s5}
==========

In conclusion, our study showed rivaroxaban to be a cost-saving treatment option when compared with enoxaparin/warfarin therapy for hospitalised acute DVT treatment in Chinese patients. The sensitivity of the cost-effectiveness model was mainly driven by the LoS of patients on enoxaparin/warfarin treatment, cost per day of hospitalisation and the difference in LoS of rivaroxaban-treated and enoxaparin/warfarin-treated patients.
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